Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma
- PMID: 37554167
- PMCID: PMC10405730
- DOI: 10.3389/fonc.2023.1193762
Combined radiotherapy and immune checkpoint inhibition for the treatment of advanced hepatocellular carcinoma
Abstract
Hepatocellular Carcinoma (HCC) is one of the most common cancers and a leading cause of cancer related death worldwide. Until recently, systemic therapy for advanced HCC, defined as Barcelona Clinic Liver Cancer (BCLC) stage B or C, was limited and ineffective in terms of long-term survival. However, over the past decade, immune check point inhibitors (ICI) combinations have emerged as a potential therapeutic option for patients with nonresectable disease. ICI modulate the tumor microenvironment to prevent progression of the tumor. Radiotherapy is a crucial tool in treating unresectable HCC and may enhance the efficacy of ICI by manipulating the tumor microenvironment and decreasing tumor resistance to certain therapies. We herein review developments in the field of ICI combined with radiotherapy for the treatment of HCC, as well as look at challenges associated with these treatment modalities, and review future directions of combination therapy.
Keywords: combination therapy; hepatocellular carcinoma; immune checkpoint inhibitors; radiotherapy; stereotactic body radiotherapy.
Copyright © 2023 Shannon, Manne, Diaz Pardo and Pawlik.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10405730/bin/fonc-13-1193762-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10405730/bin/fonc-13-1193762-g002.gif)
Similar articles
-
Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.Cancers (Basel). 2022 Apr 19;14(9):2056. doi: 10.3390/cancers14092056. Cancers (Basel). 2022. PMID: 35565184 Free PMC article. Review.
-
Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.Clin Oncol (R Coll Radiol). 2020 Oct;32(10):e194-e202. doi: 10.1016/j.clon.2020.04.004. Epub 2020 Apr 25. Clin Oncol (R Coll Radiol). 2020. PMID: 32345457
-
The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review.Cancer Treat Rev. 2023 Jul;118:102584. doi: 10.1016/j.ctrv.2023.102584. Epub 2023 May 27. Cancer Treat Rev. 2023. PMID: 37336142 Review.
-
Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy.Front Oncol. 2019 Nov 12;9:1157. doi: 10.3389/fonc.2019.01157. eCollection 2019. Front Oncol. 2019. PMID: 31799176 Free PMC article.
-
Immune checkpoint inhibitors for hepatocellular carcinoma - A game changer in treatment landscape.J Formos Med Assoc. 2022 Aug;121(8):1371-1383. doi: 10.1016/j.jfma.2022.03.017. Epub 2022 Apr 7. J Formos Med Assoc. 2022. PMID: 35400583 Review.
Cited by
-
Statin therapy: a potential adjuvant to immunotherapies in hepatocellular carcinoma.Front Pharmacol. 2024 Feb 1;15:1324140. doi: 10.3389/fphar.2024.1324140. eCollection 2024. Front Pharmacol. 2024. PMID: 38362156 Free PMC article. Review.
-
Tumor ablation induced anti-tumor immunity: destruction of the tumor in situ with the aim to evoke a robust anti-tumor immune response.Cancer Metastasis Rev. 2023 Dec;42(4):1065-1068. doi: 10.1007/s10555-023-10150-x. Cancer Metastasis Rev. 2023. PMID: 37952066 Free PMC article. Review. No abstract available.
-
Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers.Front Cell Dev Biol. 2023 Oct 3;11:1266537. doi: 10.3389/fcell.2023.1266537. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37849740 Free PMC article. Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous